Cargando…

Innate lymphocyte-induced CXCR3B-mediated melanocyte apoptosis is a potential initiator of T-cell autoreactivity in vitiligo

T-cells play a crucial role in progression of autoimmunity, including vitiligo, yet the initial steps triggering their activation and tissue damage remain unknown. Here we demonstrate increased presence of type-1 innate lymphoid cells (NK and ILC1)-producing interferon gamma (IFNγ) in the blood and...

Descripción completa

Detalles Bibliográficos
Autores principales: Tulic, Meri K., Cavazza, Elisa, Cheli, Yann, Jacquel, Arnaud, Luci, Carmelo, Cardot-Leccia, Nathalie, Hadhiri-Bzioueche, Hanene, Abbe, Patricia, Gesson, Maéva, Sormani, Laura, Regazzetti, Claire, Beranger, Guillaume E., Lereverend, Cedric, Pons, Caroline, Khemis, Abdallah, Ballotti, Robert, Bertolotto, Corine, Rocchi, Stéphane, Passeron, Thierry
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6522502/
https://www.ncbi.nlm.nih.gov/pubmed/31097717
http://dx.doi.org/10.1038/s41467-019-09963-8
Descripción
Sumario:T-cells play a crucial role in progression of autoimmunity, including vitiligo, yet the initial steps triggering their activation and tissue damage remain unknown. Here we demonstrate increased presence of type-1 innate lymphoid cells (NK and ILC1)-producing interferon gamma (IFNγ) in the blood and in non-lesional skin of vitiligo patients. Melanocytes of vitiligo patients have strong basal expression of chemokine-receptor-3 (CXCR3) isoform B which is directly regulated by IFNγ. CXCR3B activation by CXCL10 at the surface of cultured human melanocytes induces their apoptosis. The remaining melanocytes, activated by the IFNγ production, express co-stimulatory markers which trigger T-cell proliferation and subsequent anti-melanocytic immunity. Inhibiting the CXCR3B activation prevents this apoptosis and the further activation of T cells. Our results emphasize the key role of CXCR3B in apoptosis of melanocytes and identify CXCR3B as a potential target to prevent and to treat vitiligo by acting at the early stages of melanocyte destruction.